DevsHealth SL

Antimicrobial resistance is one of the world's most underestimated public health emergencies. The World Health Organization estimates that, without intervention, antibiotic-resistant bacteria could cause more deaths than current cancer diseases by 2050. Meanwhile, the traditional pharmaceutical pipeline struggles to keep pace — developing a new antibiotic requires more than a decade and billions in investment, with high failure rates. DevsHealth was built to accelerate this discovery process using artificial intelligence. The Spanish startup has developed an AI drug discovery platform focused on bacterial infections, with a specialization in Gram-negative bacteria — among the most difficult pathogens to treat because their protective membranes drastically reduce the effectiveness of existing antibiotics — and antiviral threats. The AI-based approach enables analysis of vast chemical spaces, identification of promising molecular candidates, and prediction of compound efficacy and safety in a fraction of the time required by conventional experimental methods. The business model is B2B: DevsHealth targets pharmaceutical companies, biotech firms, and R&D teams looking for technology partners to accelerate their drug discovery pipelines. The platform can be integrated into existing processes or used to launch new discovery projects from scratch, with the goal of reducing time and cost in the earliest stages of pharmaceutical development. The market for AI-powered drug discovery is growing at a rapid pace, with global investment reflecting the increasing recognition that traditional methods alone are insufficient to address the antimicrobial resistance crisis. DevsHealth enters this landscape with a clear therapeutic focus and an advanced computational approach, positioning itself as a key partner for those working to build the next generation of anti-infective drugs.